EP Patent

EP3571183B1 — 3-(phenyl)-2-(aminomethyl)-1-phenyl-2-propen-1-one derivatives as inhibitors of the n-terminal domain of the androgen receptor for treating prostate cancer

Assigned to University of California · Expires 2024-03-06 · 2y expired

What this patent protects

Patent listed against Briviact.

Drugs covered by this patent

Patent Metadata

Patent number
EP3571183B1
Jurisdiction
EP
Classification
—
Expires
2024-03-06
Drug substance claim
No
Drug product claim
No
Assignee
University of California
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.